To preliminarily elucidate the pathophysiology of TEAD1 SUMOylation in cardiac hypertrophy, NRCMs were treated with Ang II, and TEAD1 SUMOylation was detected using IP assays. Here, TEAD1 is linked to cardiac hypertrophy.